Tumor cell membrane at immune synapse

The tumor cell membrane at the immune synapse is not a single molecule but a specialized physiological junction formed between a tumor cell and an immune effector cell, such as a T cell or Natural Killer (NK) cell (Dustin, M. L., 2014, Nat Rev Immunol). This interface is characterized by the highly organized spatial arrangement of proteins into supramolecular activation clusters (SMACs), which facilitate the exchange of signals and the directed secretion of cytotoxic perforins and granzymes (Grakoui, A., et al., 1999, Science). On the tumor side, this membrane region contains critical components such as Major Histocompatibility Complex (MHC) molecules presenting tumor antigens, adhesion molecules like ICAM-1, and inhibitory ligands such as PD-L1 (Chen, L., & Flies, D. B., 2013, Nat Rev Immunol). In the context of oncology, this synapse is the primary site of action for many immunotherapies. Checkpoint inhibitors work by disrupting inhibitory signaling at this interface, while Chimeric Antigen Receptor (CAR) T-cell therapies are engineered to form a functional, albeit artificial, synapse with the tumor membrane to trigger cell lysis (Dieckmann, N. M., et al., 2016, Phil. Trans. R. Soc. B). Because this entry describes a complex cellular structure and location rather than a discrete protein or gene, it is classified as a 'location' or 'interface' rather than a specific therapeutic target in the canonical sense. Understanding the molecular topography of the tumor membrane at this synapse is essential for overcoming resistance mechanisms, such as the downregulation of antigen-presenting machinery or the physical exclusion of immune cells from the tumor microenvironment.

Other names

Tumor-immune interfaceImmunological synapse (IS)Cancer-immune synapseSupramolecular activation cluster (SMAC)

Modulation of receptor-ligand interactions at the interface between immune cells and tumor cells to enhance or restore anti-tumor immunity, often by blocking inhibitory checkpoints or facilitating physical engagement via bispecific antibodies or CAR-T cells.